Excited to share our new report in Nature Communications! We develop general engineering guidelines for building microbe-derived ribosomes in the laboratory workhorse E. coli. nature.com/articles/s4146…

My lab combines biotechnology and entrepreneurship to build technologies and deploy them for maximum impact. We have a postdoc position open to work on delivering DNA (e.g. plasmids, ASOs) to specific cell types throughout the body. Contact if interested: appliedbiotechlab.com

Lots of people on Twitter & on the news are trying to make vaccine hesitancy political. But in fact, it's not really that political: wealthier, more-educated states tend to have higher rates of vaccine uptake. Socioeconomic inequity has long been a driver of vaccine hesitancy.

LAMP-Seq with 1-enzyme protocol out today go.nature.com/3y85GfE, grateful to colleagues @ Bonn&Boston! Kerstin Ludwig Ricarda Schmithausen David Li @ronhollstein Mikołaj Słabicki Nina Ishorst Lara Hochfeld Eva Beins @InesKalt @MaxSticks7 @ern_esth Jacob Borrajo Jonathan Strecker Michael Hölzel Feng Zhang

Amplification is to NGS, as re-reading is to single molecule proteomics 🤯 congrats to cees dekker - also at @ceesdekker.bsky.social and colleagues — single molecule proteomics will power a new biotech revolution biorxiv.org/content/10.110…

The biotech startup ecosystem is dominated by a culture that requires every executive team to have done it before. Many companies are even created by VCs internally. But a new model is emerging -- the founder-led biotech. Why I think this is the future: pillar.vc/news/the-futur…

Are there any VCs/funds dedicated to AI safety? Seems wise to invest similar order of magnitude into AI safety as AI itself… I wonder what the budget gap looks like today 👀

🚨 Today, we’re thrilled to share our study expanding the gene editing toolbox to enable virtually any kind of edit in gene transcripts at the order of thousands of bases. A thread 🧵👇(1/n) biorxiv.org/content/10.110…

𝐒𝐩𝐥𝐢𝐜𝐞 𝐞𝐝𝐢𝐭𝐢𝐧𝐠 𝐚𝐥𝐥𝐨𝐰𝐬 𝐦𝐮𝐥𝐭𝐢-𝐤𝐢𝐥𝐨𝐛𝐚𝐬𝐞 𝐑𝐍𝐀 𝐞𝐝𝐢𝐭𝐢𝐧𝐠 Scientists from Massachusetts Institute of Technology (MIT) and Amber Bio share details of their new Splice Editing platform on the pre-printer server BioXriv. Read more here: surl.li/kioxf

Hot on the heels of their Seed announcement, Amber Bio is unveiling Splice Editing – a novel gene editing method leveraging endogenous splicing machinery and newly discovered CRISPR-Cas systems to achieve large edits. Preprint by Jacob Borrajo Basem Al-Shayeb, Ph.D. 🧬 & team👇cc Vineeta Agarwala

Amber Bio pre-print alert 🚨 Jacob Borrajo Basem Al-Shayeb, Ph.D. 🧬 et al. show us how to introduce multi-Kb inserts into endogenous mRNA by co-opting the spliceosome 1/n biorxiv.org/content/10.110…

A potentially high-efficiency alternative to making large genome edits: making large RNA edits via splicing! Very cool proof-of-concept from Jacob Borrajo Kamyab Javanmardi, Ph.D. ⚛️ Basem Al-Shayeb, Ph.D. 🧬 & Blainey Lab in bioRxiv